Piper Remains Constructive on Intra-Cellular Therapies (ITCI) Following Q3 Report; Affirms at 'Overweight'

Intra-Cellular Therapies (ITCI) Tops Q3 EPS by 14c

Intra-Cellular Therapies (NASDAQ: ITCI) reported Q3 EPS of ($0.70), $0.14 better than the analyst estimate of ($0.84). Revenue for the quarter came in at $4.36 thousand versus the consensus estimate of $50 thousand.

For earnings history and earnings-related data on Intra-Cellular Therapies (ITCI) click here.